Literature DB >> 16026319

Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure.

Zoltan Ungvári1, Sachin A Gupte, Fabio A Recchia, Sándor Bátkai, Pál Pacher.   

Abstract

Heart failure is the major cause of hospitalization, morbidity and mortality worldwide. Previous experimental and clinical studies have suggested that there is an increased production of reactive oxygen species (ROS: superoxide, hydrogen peroxide, hydroxyl radical) both in animals and in patients with acute and chronic heart failure. The possible source of increased ROS in the failing myocardium include xanthine and NAD(P)H oxidoreductases, cyclooxygenase, the mitochondrial electron transport chain and activated neutrophils among many others. The excessively produced nitric oxide (NO) derived from NO synthases (NOS) has also been implicated in the pathogenesis of chronic heart failure (CHF). The combination of NO and superoxide yields peroxynitrite, a reactive oxidant, which has been shown to impair cardiac function via multiple mechanisms. Increased oxidative and nitrosative stress also activates the nuclear enzyme poly(ADP-ribose) polymerase (PARP), which importantly contributes to the pathogenesis of cardiac and endothelial dysfunction associated with myocardial infarction, chronic heart failure, diabetes, atherosclerosis, hypertension, aging and various forms of shock. Recent studies have demonstrated that pharmacological inhibition of xanthine oxidase derived superoxide formation, neutralization of peroxynitrite or inhibition of PARP provide significant benefit in various forms of cardiovascular injury. This review discusses the role of oxidative/nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16026319      PMCID: PMC2225532          DOI: 10.2174/1570161054368607

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  119 in total

1.  NO and superoxide: opposite ends of the seesaw in cardiac contractility.

Authors:  Joseph Bonaventura; Andrew Gow
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-16       Impact factor: 11.205

Review 2.  Mitochondrial energy metabolism in heart failure: a question of balance.

Authors:  Janice M Huss; Daniel P Kelly
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

3.  Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure.

Authors:  U E Ekelund; R W Harrison; O Shokek; R N Thakkar; R S Tunin; H Senzaki; D A Kass; E Marbán; J M Hare
Journal:  Circ Res       Date:  1999-09-03       Impact factor: 17.367

4.  Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy.

Authors:  Linda B Stull; Michelle K Leppo; Luke Szweda; Wei Dong Gao; Eduardo Marbán
Journal:  Circ Res       Date:  2004-10-21       Impact factor: 17.367

5.  Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling.

Authors:  Shakil A Khan; Kwangho Lee; Khalid M Minhas; Daniel R Gonzalez; Shubha V Y Raju; Ankit D Tejani; Dechun Li; Dan E Berkowitz; Joshua M Hare
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-14       Impact factor: 11.205

6.  Superoxide and peroxynitrite inactivate aconitases, but nitric oxide does not.

Authors:  A Hausladen; I Fridovich
Journal:  J Biol Chem       Date:  1994-11-25       Impact factor: 5.157

7.  Substrate control of free radical generation from xanthine oxidase in the postischemic heart.

Authors:  Y Xia; J L Zweier
Journal:  J Biol Chem       Date:  1995-08-11       Impact factor: 5.157

8.  Deficiency of iNOS does not attenuate severe congestive heart failure in mice.

Authors:  Steven P Jones; James J M Greer; Paul D Ware; Jiang Yang; Kenneth Walsh; David J Lefer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-08-19       Impact factor: 4.733

9.  Improvement of cardiac function by allopurinol in patients undergoing cardiac surgery.

Authors:  P Castelli; A M Condemi; C Brambillasca; P Fundarò; M Botta; M Lemma; P Vanelli; C Santoli; S Gatti; E Riva
Journal:  J Cardiovasc Pharmacol       Date:  1995-01       Impact factor: 3.105

10.  Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting.

Authors:  J G Coghlan; W D Flitter; S M Clutton; R Panda; R Daly; G Wright; C D Ilsley; T F Slater
Journal:  J Thorac Cardiovasc Surg       Date:  1994-01       Impact factor: 5.209

View more
  70 in total

1.  Mitochondria-derived superoxide and voltage-gated sodium channels in baroreceptor neurons from chronic heart-failure rats.

Authors:  Huiyin Tu; Jinxu Liu; Zhen Zhu; Libin Zhang; Iraklis I Pipinos; Yu-Long Li
Journal:  J Neurophysiol       Date:  2011-11-09       Impact factor: 2.714

Review 2.  The electrophile responsive proteome: integrating proteomics and lipidomics with cellular function.

Authors:  Ashlee N Higdon; Aimee Landar; Stephen Barnes; Victor M Darley-Usmar
Journal:  Antioxid Redox Signal       Date:  2012-04-18       Impact factor: 8.401

Review 3.  Metabolic alterations induce oxidative stress in diabetic and failing hearts: different pathways, same outcome.

Authors:  David Roul; Fabio A Recchia
Journal:  Antioxid Redox Signal       Date:  2015-04-30       Impact factor: 8.401

4.  Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure.

Authors:  Pál Pacher; Lucas Liaudet; Jon G Mabley; Attila Cziráki; György Haskó; Csaba Szabó
Journal:  Int J Mol Med       Date:  2006-02       Impact factor: 4.101

Review 5.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

Review 6.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

Review 7.  CB1 cannabinoid receptor inhibition: promising approach for heart failure?

Authors:  Partha Mukhopadhyay; Rajesh Mohanraj; Sándor Bátkai; Pál Pacher
Journal:  Congest Heart Fail       Date:  2008 Nov-Dec

8.  Improvement of aging-associated cardiovascular dysfunction by the orally administered copper(II)-aspirinate complex.

Authors:  Tamás Radovits; Domokos Gerö; Li-ni Lin; Sivakkanan Loganathan; Torsten Hoppe-Tichy; Csaba Szabó; Matthias Karck; Hiromu Sakurai; Gábor Szabó
Journal:  Rejuvenation Res       Date:  2008-10       Impact factor: 4.663

9.  Timing and duration of interventions in clinical trials for patients with hospitalized heart failure.

Authors:  Catherine N Marti; Gregg C Fonarow; Mihai Gheorghiade; Javed Butler
Journal:  Circ Heart Fail       Date:  2013-09-01       Impact factor: 8.790

10.  Type 5 adenylyl cyclase increases oxidative stress by transcriptional regulation of manganese superoxide dismutase via the SIRT1/FoxO3a pathway.

Authors:  Lo Lai; Lin Yan; Shumin Gao; Che-Lin Hu; Hui Ge; Amy Davidow; Misun Park; Claudio Bravo; Kousaku Iwatsubo; Yoshihiro Ishikawa; Johan Auwerx; David A Sinclair; Stephen F Vatner; Dorothy E Vatner
Journal:  Circulation       Date:  2013-03-27       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.